Axsome Therapeutics announced on February 17, 2026 that it has reached a settlement with Alkem Laboratories Ltd. to resolve patent litigation surrounding its wake‑promoting drug SUNOSI (solriamfetol).
Under the agreement, Alkem will receive a license to market a generic version of SUNOSI beginning on or after September 1, 2040 if pediatric exclusivity is granted, or March 1, 2040 if not, subject to FDA approval and customary conditions. The settlement was filed in the United States District Court for the District of New Jersey and will be reviewed by the U.S. Federal Trade Commission and the Department of Justice.
The settlement clarifies Axsome’s intellectual‑property rights and establishes a clear licensing timeline, but it does not alter SUNOSI’s current market position. By setting a definitive generic entry window, the company reduces uncertainty around future competition and reinforces its strategy of protecting key assets while managing patent risks.
Axsome’s recent financial performance provides context for the settlement’s significance. The company reported preliminary Q4 2025 revenue of $196.0 million, beating analyst estimates of $191.72 million, and preliminary full‑year 2025 revenue of $638.5 million, also exceeding expectations. Gross margin for Q4 2025 was 91.86 percent, reflecting efficient cost management. CEO Herriot Tabuteau highlighted the company’s accelerating commercial momentum and focus on cost discipline and pipeline progress.
The SUNOSI settlement is one of several patent litigations involving the drug; other legal challenges remain pending. Axsome’s portfolio also includes the major depressive disorder treatment Auvelity, the migraine therapy AXS‑07, and the recently launched Symbravo. The settlement provides long‑term stability for SUNOSI, securing intellectual property and mitigating potential generic competition until 2040, thereby supporting the company’s revenue trajectory and competitive positioning.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.